English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/128118
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections

AutorDíez-Martínez, Roberto ; García-Fernández, Esther; Manzano, Miguel; Martínez, Ángel; Domenech, Mirian ; Vallet-Regí, María; García, Pedro
Fecha de publicación18-ene-2016
EditorNature Publishing Group
CitaciónScientific Reports 6, Article number: 19525 (2016)
ResumenDrug-loaded nanoparticles (NPs) can improve infection treatment by ensuring drug concentration at the right place within the therapeutic window. Poly(lactic-co-glycolic acid) (PLGA) NPs are able to enhance drug localization in target site and to sustainably release the entrapped molecule, reducing the secondary effects caused by systemic antibiotic administration. We have loaded auranofin, a gold compound traditionally used for treatment of rheumatoid arthritis, into PLGA NPs and their efficiency as antibacterial agent against two Gram-positive pathogens, Streptococcus pneumoniae and Streptococcus pyogenes was evaluated. Auranofin-PLGA NPs showed a strong bactericidal effect as cultures of multiresistant pneumococcal strains were practically sterilized after 6 h of treatment with such auranofin-NPs at 0.25 μM. Moreover, this potent bactericidal effect was also observed in S. pneumoniae and S. pyogenes biofilms, where the same concentration of auranofin-NPs was capable of decreasing the bacterial population about 4 logs more than free auranofin. These results were validated using a zebrafish embryo model demonstrating that treatment with auranofin loaded into NPs achieved a noticeable survival against pneumococcal infections. All these approaches displayed a clear superiority of loaded auranofin PLGA nanocarriers compared to free administration of the drug, which supports their potential application for the treatment of streptococcal infections.
Descripción12p.-7 fig.-2 tab.
Versión del editorhttp://dx.doi.org/ 10.1038/srep19525
URIhttp://hdl.handle.net/10261/128118
DOI10.1038/srep19525
ISSN2045-2322
E-ISSN2045-2322
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Díez-Martínez et al-Sci Rep 2016.pdfArtículo principal1,06 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.